Blenrep Returns With New FDA Approval in R/R Multiple Myeloma
The Food and Drug Administration (FDA) has approved Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory (R/R) multiple myeloma.
Blenrep consists of a B-cell maturation antigen (BCMA)-directed antibody and microtubule inhibitor conjugate.
The new approval is based on data from the phase 3 DREAMM-7 trial.
The drug had initially received accelerated approval in 2020 for R/R multiple myeloma based on data from the DREAMM-2 study, however, was subsequently removed from the market in 2022 after a confirmatory trial (DREAMM-3) failed to meet the requirements for traditional approval by the FDA.
No additional quote available
Author summary: Blenrep approved for R/R multiple myeloma treatment.
More News
- 238,000 visitors attended Frankfurt Book Fair 2025 | PrintWeekIndia
- From WNBA Court To Playmate Glam: Check Out Kysre Gondrezick’s Sexiest Photos
- Travel-Ready Base Layers That Simplify Packing
- Trump administration quietly purges ICE leaders in five cities, including Denver: Sources
- The Angel Ball Honors Tina Knowles
- Al-Nassr 1-2 Al-Ittihad: Report, result and goals as Karim Benzema scores to knock Cristiano Ronaldo's side out of Kings Cup
- Charlie Kirk’s accused killer allowed to wear street clothes in court
- Tomago Aluminium is more than just a smelter, it's a strategic asset
- Eintracht Frankfurt Borussia Dortmund 28 10 2025 Live Score and Match Summary
- State Rep. Marcus Wiedower Resigns; Special Election Will Be Called - Flagpole